HNSCC Clinical Trials

31 recruiting

HNSCC Trials at a Glance

50 actively recruiting trials for hnscc are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 27 trials, with the heaviest enrollment activity in Pittsburgh, Guangzhou, and San Antonio. Lead sponsors running hnscc studies include West China Hospital, Dan Zandberg, and Memorial Sloan Kettering Cancer Center.

Browse hnscc trials by phase

Treatments under study

About HNSCC Clinical Trials

Looking for clinical trials for HNSCC? There are currently 31 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new HNSCC trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about HNSCC clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 50 trials

Recruiting
Not Applicable

Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)
Sun Yat-sen University50 enrolled1 locationNCT06630780
Recruiting
Not Applicable

Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors

HNSCC
Grit Biotechnology32 enrolled1 locationNCT06190275
Recruiting
Phase 1Phase 2

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Non-small Cell Lung Cancer (NSCLC)Pancreatic Adenocarcinoma+2 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.230 enrolled13 locationsNCT05985655
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 1

A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors

Head and Neck CancerHNSCCColo-rectal Cancer+4 more
ALX Oncology Inc.170 enrolled7 locationsNCT07085091
Recruiting
Phase 1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 2

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

Margin AssessmentSquamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Medical University of South Carolina30 enrolled1 locationNCT07149207
Recruiting
Phase 2

Window of Opportunity in Preserving Laryngeal Function Trial

Hypopharyngeal Squamous Cell CarcinomaLocally Advanced Laryngeal Squamous Cell CarcinomaHead and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
Matthew Spector87 enrolled1 locationNCT07423078
Recruiting

Matching Primary Tumor and Blood Gene Expression Analysis of HPV-negative Squamous Head and Neck Cancers

Head and Neck (HNSCC)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano300 enrolled2 locationsNCT07512921
Recruiting
Phase 2

Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC

Head and Neck Squamous Cell Carcinoma (HNSCC)Squamous Cell Carcinoma of the Head and Neck
Dana-Farber Cancer Institute32 enrolled2 locationsNCT07465276
Recruiting
Phase 1

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Head and Neck CancerHead and Neck Squamous Cell CarcinomaHNSCC+3 more
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT04722523
Recruiting
Phase 2

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC)
Regeneron Pharmaceuticals120 enrolled2 locationsNCT06769698
Recruiting
Phase 1Phase 2

DCSZ11 in Combination With Standard Therapy in Advanced or Metastatic Solid Tumors

Solid TumorsHNSCCDCSZ11
West China Hospital9 enrolled1 locationNCT07035249
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 2

Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC

Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
University Health Network, Toronto102 enrolled1 locationNCT05414032
Recruiting
Phase 1Phase 2

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Colorectal CarcinomaBladder CancerSolid Tumor Malignancies+2 more
Tasca Therapeutics150 enrolled13 locationsNCT07030257
Recruiting
Phase 1

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Ovarian CancerCervical CancerEndometrial Cancer+6 more
Normunity AccelCo, Inc.150 enrolled9 locationsNCT07182149
Recruiting
Phase 2

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Dan Zandberg15 enrolled1 locationNCT06052839
Recruiting
Phase 2

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)
Dan Zandberg80 enrolled1 locationNCT04080804
Recruiting
Phase 1

Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer

Head and Neck CancerSolid TumorsHNSCC+3 more
VLP Therapeutics41 enrolled1 locationNCT06736379